Evogene (EVGN) Non Operating Income (2013 - 2026)
Evogene (EVGN) posted Non Operating Income of -$2.7 million for Q1 2026, down 1505.33% sequentially from -$169000.0 in Q4 2025, and down 340.94% YoY from $1.1 million in Q1 2025.
Evogene (EVGN) Non Operating Income (2013 - 2026) Analysis & Trends
Evogene has reported Non Operating Income for 14 years, with the latest figure at -$2.7 million in Q1 2026.
- Quarterly Non Operating Income fell 340.94% year-over-year to -$2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 149.63% YoY) and the FY2025 annual result came in at $575000.0, down 85.75% from the prior year.
- Non Operating Income declined to -$2.7 million in Q1 2026 per EVGN's latest filing, from -$169000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $4.5 million in Q4 2024 and troughed at -$2.7 million in Q1 2026.
- A 5-year average of $376764.7 and a median of $97000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income soared 1074.57% in 2024, then plunged 505.15% in 2025.
- Over 5 years, Non Operating Income stood at -$149000.0 in 2022, then tumbled by 208.72% to -$460000.0 in 2023, then jumped by 1074.57% to $4.5 million in 2024, then sank by 103.77% to -$169000.0 in 2025, then plunged by 1505.33% to -$2.7 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$2.7 million, -$169000.0, and -$135000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.71 Mn |
| Dec 31, 2025 | -169,000.00 |
| Sep 30, 2025 | -135,000.00 |
| Jun 30, 2025 | -393,000.00 |
| Mar 31, 2025 | 1.13 Mn |
| Dec 31, 2024 | 4.48 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | -460,000.00 |
| Sep 30, 2023 | 320,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Mar 31, 2023 | -230,000.00 |
| Dec 31, 2022 | -149,000.00 |
| Sep 30, 2022 | -61,000.00 |
| Jun 30, 2022 | 2.03 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | -733,000.00 |
| Sep 30, 2021 | -346,000.00 |
| Jun 30, 2021 | -893,000.00 |